Changes in hypercoagulability by asparaginase: A randomized study between two asparaginases

Blood Coagulation and Fibrinolysis

Volumn 17, Issue 2, 2006, Pages 139-146

  Appel, Inge M ^a   Hop, Wim C J ^b   Pieters, Rob ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acute lymphoblastic leukaemia; Hemostasis; Hypercoagulability; L asparaginase; Randomized study

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBIN III; ASPARAGINASE; D DIMER; DAUNORUBICIN; FIBRIN; FIBRINOGEN; METHOTREXATE; PLASMINOGEN; PREDNISONE; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLEEDING; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG MECHANISM; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; HYPOFIBRINOGENEMIA; INFANT; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; BLOOD COAGULATION; CHILD; CHILD, PRESCHOOL; DAUNORUBICIN; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; PREDNISONE; RISK FACTORS; THROMBOSIS; VINCRISTINE;

EID: 33646116050     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000214709.11492.ec     Document Type: Article

References (33)

1. Ramsay NK, Coccia PF, Krivit W, Nesbit ME, Edson JR. The effect of L-asparaginase of plasma coagulation factors in acute lymphoblastic leukemia. Cancer 1977; 40:1398-1401.
2. Mitchell LG, Hoogendoorn H, Giles AR, Vegh P, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency. Blood 1994; 83:386-391.
3. Nowak-Gottl U, Wolff JEA, Kuhn N, Boos J, Lilieweiss V, Schwabe D, et al. Enhanced thrombingeneration, P-von Willebrand factor, P-fibrin, D-Dimer and P-plasminogen activator inhibitor 1: predictive for venous thrombosis in asparaginase treated children. Fibrinolysis 1994; 8:66-68.
4. Athale UH, Chan AKC. Thrombosis in children with acute lymphoblastic leukemia Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effect of the disease and therapy. Thromb Res 2003; 11:199-212.
5. Nowak-Gottl U, Wermes C, Junker R, Koch HG, Schobbes R, Fleischhack G, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia. Blood 1999; 93:1595-1599.
6. Kirschke R, Nurnberger W, Eckhof-Donovan S, Nurnberger I, Gobel U. Coagulation and fibrinolysis in children with acute lymphoblastic leukemia treated according to the COALL-05-92-protocol. Klin Padiatr 1998; 210:285-290.
7. Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 2002; 99:2734-2739.
8. Asselin BL. The three aspraginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol 1999; 457:621-629.
9. Eden OB, Shaw MP, Lilleyman JS, Richards S. Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia. Med Pediatr Oncol 1990; 18:497-502.
10. Nowak-Gottl U, Kuhn N, Wolff JE, Boos J, Kehrel B, Rath B, et al. Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children. Eur J Haematol 1996; 56:35-38.
11. Risseeuw-Appel IM, Dekker I, Hop WC, Hahlen K. Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: a randomized study. Med Pediatr Oncol 1994; 23:335-343.
12. Risseeuw-Appel IM, Dekker I, Stigter RL, Hop WCJ, Hählen K. Progressive elevation of Antithrombin III levels during acute lymphoblastic leukemia induction treatment, not followed by a decrease in Antithrombin III after addition of Asparaginase: a randomized study between Escherichia Coli and Erwinia Asparaginase. Int J Ped Haematol/Oncol 1996; 3: 66-74.
13. Kamps WA, Veerman AJP, van Wering ER, van Weerden JF, Slater R, van der Does-van den Berg A. Long term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia. Leukemia 2000; 14:2240-2246.
14. Reiter A, Schrappe M, Sauter S, Ludwig WD, Harbott J, Ritter J, et al. Treatment strategy and results of non-B acute lymphoblastic leukeima in the German-Austrian-multicenter trial ALL/NHL-BFM 86. Med Ped Oncol 1992; 20:390.
15. Adreotti F, Kluft C. Circadian variation of fibrinolytic activity in blood. Chronobiol-Int 1991; 8:336-351.
16. Ries M, Klinge J, Rauch R. Age-related reference values for activation markers of the coagulation and fibrinolytic system. Thromb Res 1997; 85:341-344.
17. Pelzer H, Schwartz A, Stuber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991; 65:153-159.
18. Pelzer H, Schwartz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 50:101-106.
19. Matsuda T, Ogawara M, Miura R, Seki T, Matsumoto T, Teramura Y, Nakamura K. Selective determination of alpha2-plasma inhibitor activity in plasma using chromogenic substrate. Thromb Res 1984; 33:379-388.
20. Knos M, Friberger P. Methods for plasminogen determination in human plasma and for streptokinase standardization. In: Davidson et al., editors. Progress in chemical fibrinolysis and thrombolysis. Edinburgh: Chuchill Livingstone; 1979. pp. 154-158.
21. Holvoet P, de Boer A, Verstreken M, Collen D. An enzyme limked immunosorbent assay (ELISA) for the measurement of plasmin-alpha 2-antiplasmin complex in human plasma: application to the detection of in-vivo activation of the fibrinolytic system. Thromb Haemost 1986; 56:124-127.
22. Heaton DC, Billings JD, Hickton CM. Assessment of D-dimer assays for the diagosis of deep vein thrombosis. J Lab Clin Med 1987; 110:588-591.
23. Bick RL, Baker WF. Diagnostic efficacy of the D-dimer assay in disseminated intravascular coagulation. Thromb Res 1992; 65:785-790.
24. Clauss A. Determination of fibrinogen[in German]. Acta Haemat 1957; 17:237-246.
25. Mall V, Thomas KB, Sauter S, Niemeyer CM, Sutor AH. Effect of glucocorticosteroids, E. Coli- and Erwinia L-Asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia. Klin Padiatr 1999; 211:205-210.
26. Dal Bo Zanon R, Fornasiero L, Boscaro M, Capellato G, Fabris F, Girolami A. Increased F VIII associated activities in Cushing's syndrome: a probable hypercoagulable state. Thromb Haemost 1982; 47:116-117.
27. Albertsen B, Schroder H, Ingerslev J, Jakobsen P, Avramis AI, Muller HJ, et al. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br J Haematol 2001; 115:983-990.
28. Nowak-Gottl U, Werber G, Ziemann D, Ahlke E, Boos J. Influence of two different Escherichia Coli Asparaginase preparations on fibrinolytic proteins in childhood ALL. Haematologica 1996; 81:127-131.
29. Hafner G, Schinzel H, Ehrental W, Wagner C, Konheiser U, Zotz R, et al. Influence of blood sampling from venipunctures and catheter systems on serial determinations of prothrombin activation fragment 1+2 and thrombin-antithrombin III complex. Ann Hematol 1993; 67:121-125.
30. Sartori TM, Maurizio PG, Sara P, Ugolino L, Annalisa A, Panagiotis T. Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi. J Heart Lung Transplant 1999; 8:693-700.
31. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993; 11:1780-1786.
32. Leone G, Gugliotta L, Mazzucconi MG, De Stefano V, Belmonte MM, Dragoni F, et al. Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-asparaginase: a GIMEMA study. Thromb Haemost 1993; 69:12-15.
33. Nowak-Gottl U, Ahlke E, Schulze-Westhoff P, Boos J. Changes in coagulation and fibrinolysis in childhood ALL: a two-step dose reduction of one E. coli asparaginase preparation. Br J Haematol 1996; 95:123-126.